Internal Data Sheds Light into Current State of Allergy Treatment

The number of people suffering with allergies continues to increase with an estimated 20 percent of the Australian population suffering from at least one allergic disease. To put that into perspective, Australia has an estimated population of nearly 25 million, so that means 5 million Australians are affected.

With World Allergy Week in full swing, we decided to take a look at our internal data to see if there has been any significant trends as the number of sufferers continues to grow. After analysing data of tens of thousands of patients in Australia since 2014, here’s what we found:

  • Sublingual immunotherapy treatment (SLIT) is becoming the preferred choice of treatment: ​Over the last three years, Gamma Allergy has seen an increase in the amount of SLIT In 2015, 40 percent of patients were on SLIT. Currently, the percentage of patients on SLIT is approximately 45 percentage, representing a 12.5 percent increase. While subcutaneous immunotherapy treatment (SCIT) has a clinical history of over 100 years and is the traditional method of allergy immunology, SLIT is gaining strong traction as an alternative treatment method because the drops can be self-administered at home. This method allows the body to become tolerant of the allergen sublingually and through the stomach lining, as opposed to directly via the bloodstream in SCIT, eliminating the risk of anaphylactic reactions.


  • Increase in the prescription of Australian specific mixtures: ​In the last year, over 70 percent of Gamma Allergy’s orders have included the prescription of an Australian specific mixture. Addressing the specific needs of Australian patients, Gamma Allergy created two different grass mixtures. NSW Grass Mix is 25 percent Bahia, 25 percent Bermuda, 25 percent Johnson and 25 percent Perennial Rye. In addition, QLD Grass Mix is 50 percent Bahia, 25 percent Bermuda and 25 percent Johnson. While Bahia and Bermuda are both subtropical perennial grasses native to Mexico and South America, these grasses have been naturalised in Australia for their quality as a soil stabiliser to control erosion and their low maintenance properties. While treatment using current serums that do not contain Bahia and Bermuda have been successful, the common feedback from healthcare professionals is that treatment would be more effective with a serum that contained a higher concentration of Bahia and Bermuda in its grass blend. This is evidenced in the analysis on Gamma Allergy’s internal data. Gamma Allergy also created an Australian-specific Dust Mite Mix, containing a higher concentration of D. Pteronyssinus to D. Farinae (70 percent/30 percent), which is becoming increasingly popular.


  • SCIT Alum versus SCIT Aqueous:​ Gamma Allergy’s Alum range covers most allergens used in Australia and because of its shorter build up time, it is preferred and most commonly used in Australia. Due to the expansion of Gamma Allergy’s Alum product range, the company has seen a 17 percent increase in the past six months. Both injection products have similar efficacy, however they are manufactured slightly different. As a result, Alum requires less weekly injections before going to monthly. Gamma Allergy’s supply of immunotherapy treatment, including Alum, comes from North America and as a result provides a strong and stable supply to its customers.
By | 2018-04-24T08:21:30+00:00 April 24th, 2018|